Skip to main content

Table 1 Distribution of the studied cases according to different clinical parameters (n = 89)

From: B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels

 

No. (%)

Sex

 Male

26 (29.2%)

 Female

63 (70.8%)

Age (years)

 Mean ± SD.

50.1 ± 9.9

 Median (min.–max.)

50 (27–65)

BMI (kg/m2)

 Mean ± SD.

26.9 ± 2

 Median (min.–max.)

27.1(22.9–29.9)

HCV PCR

 Mean ± SD.

918883.5 ± 1228408

 Median (min.–max.)

336000 (5592–5330000)

Liver echogenicity

 Normal

61 (68.5%)

 Cirrhotic

28 (31.5%)

Spleen (US)

 Normal

79 (88.8%)

 Enlarged

10 (11.2%)

FIB4 score

 Mean ± SD.

1.7 ± 0.9

 Median (min.–max.)

1.5 (0.6–5.2)

APRI score

 Mean ± SD.

0.6 ± 0.4

 Median (min.–max.)

0.5 (0.1–1.9)

Type of drugs

 SOF + DAC

63(70.8%)

 SOF + DAC + RIB

26(29.2%)

  1. SD standard deviation, BMI body mass index, APRI score aspartate aminotransferase-to-platelet ratio index score, SOF sofosbuvir, DAC daclatasvir, RIB ribavirin